In the journal Clinical Cancer Research, a group of researchers, including current and past OCRF grantees Anil Sood and Gabriel Lopez-Berestein, evaluated the prognostic value of fibroblast growth factor receptor 4 (FGFR4) protein expression in patients with advanced-stage, high-grade serous ovarian cancer.
They found that FGFR4 is a prognostic marker for the disease. Furthermore, silencing FGFR4 significantly decreases ovarian tumor growth. These findings suggest that targeting those ovarian cancer cells with high levels of FGFR4 is a new therapeutic target, and may improve patient survival.
Read the abstract here.